ABIOMED, Inc. (ABMD)
(Delayed Data from NSDQ)
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra (IART) Q1 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.
QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.
Integra LifeSciences (IART) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 8.82% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Apr 28 Earnings Roster: ABMD, SYK & More
by Trina Mukherjee
The MedTech companies' Q1 results are likely to reflect solid rebound in base business sales. Let's see how ABMD, SYK, BAX and DXCM are poised ahead of their earnings releases.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.
Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.
Here's Why You Should Retain Integra (IART) Stock For Now
by Zacks Equity Research
Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.
Globus Medical (GMED) Stock Fell on Preliminary Q1 Sales Results
by Zacks Equity Research
Globus Medical's (GMED) Q1 preliminary sales results reflect an increase in procedural volumes along with growth in Enabling Technologies business.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.
Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Here's Why You Should Hold on to Illumina (ILMN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Zacks Industry Outlook Highlights Alcon, STERIS and Abiomed
by Zacks Equity Research
Alcon, STERIS and Abiomed have been highlighted in this Industry Outlook article.
Merit Medical's (MMSI) Latest Launch to Boost Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest well-designed tray is expected to simplify the thoracostomy procedure and reduce treatment time, especially in critical situations.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Patterson Companies (PDCO) Moves Up 12.5%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) robust segmental performance and strong prospects in the dental space.
Thermo Fisher (TMO) Debuts GMP-Manufactured Cas9 Protein
by Zacks Equity Research
Thermo Fisher's (TMO) Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most. Yet, demand for non-COVID businesses is on the decline with the new COVID variant disrupting the trend.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity
by Zacks Equity Research
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Henry Schein (HSIC) Stock Moves Up 20.6%: What's Driving It?
by Zacks Equity Research
Henry Schein's (HSIC) stock rallied on strong fourth-quarter performance and bullish 2022 EPS guidance.